Lysosome-mediated degradation of a distinct pool of lipid droplets during hepatic stellate cell activation

Received for publication, January 26, 2017, and in revised form, June 14, 2017 Published, Papers in Press, June 14, 2017, DOI 10.1074/jbc.M117.778472

Maidina Tuohetahuntila‡, Martijn R. Molenaar‡, Bart Spee§, Jos F. Brouwers‡, Richard Wubbolts†, Martin Houweling†, Cong Yan§, Hong Du§, Brian C. VanderVen†, Arie B. Vaandrager†, and J. Bernd Helms†

From the ‡Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, 3584 CM, Utrecht, The Netherlands, §Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, 3584 CM, Utrecht, The Netherlands, ¶Indiana University School of Medicine, Indianapolis, Indiana 46202, and †Department of Microbiology and Immunology, Cornell University, CS 181 Veterinary Medicine Center, Ithaca, New York 14853

Edited by George M. Carman

Activation of hepatic stellate cells (HSCs) is a critical step in the development of liver fibrosis. During activation, HSCs lose their lipid droplets (LDs) containing triacylglycerols (TAGs), cholesteryl esters, and retinyl esters (REs). We previously provided evidence for the presence of two distinct LD pools, a preexisting and a dynamic LD pool. Here we investigate the mechanisms of neutral lipid metabolism in the preexisting LD pool. To investigate the involvement of lysosomal degradation of neutral lipids, we studied the effect of lalistat, a specific lysosomal acid lipase (LAL/Lipa) inhibitor on LD degradation in HSCs during activation in vitro. The LAL inhibitor increased the levels of TAG, cholesteryl ester, and RE in both rat and mouse HSCs. Lalistat was less potent in inhibiting the degradation of newly synthesized TAG species as compared with a more general lipase inhibitor orlistat. Lalistat also induced the presence of RE-containing LDs in an acidic compartment. However, targeted deletion of the Lipa gene in mice decreased the liver levels of RE, most likely as the result of a gradual disappearance of RE-containing LDs in an acidic compartment. The majority of vitamin A (retinol) is stored as retinyl esters (REs) in specific liver cells, the so-called hepatic stellate cells (HSCs) (1, 2). HSCs are located in the spaces of Disse, between sinusoidal endothelial cells and hepatocytes. In a healthy liver, HSCs contain large lipid droplets filled with REs, triacylglycerols (TAGs), and cholesteryl esters (CEs). After liver injury, quiescent HSCs can transdifferentiate into activated cells with a myofibroblastic phenotype (1). Activated macrophages in concert with HSCs may initiate this transition by secreting cytokines such as transforming growth factor β (TGF-β), which stimulate the synthesis of matrix proteins and the release of retinoids by HSCs (1, 3). The loss of retinoids is associated with a gradual disappearance of LDs in HSCs. We previously reported that LD degradation in activated rat HSCs occurs in two phases (4). Upon activation of HSCs, the LDs reduce in size but increase in number during the first 7 days in culture. In the second phase the lipid droplets disappear. Raman and lipidomic studies showed that in the initial phase of HSC activation, the REs disappear rapidly, whereas the TAG content transiently increases (4). This increase in TAGs in rat HSCs is predominantly caused by a large and specific increase in polyunsaturated fatty acid (PUFA)-containing triacylglycerol species during the first 7 days in culture, mediated by the increase in the ratio of the PUFA-specific fatty acid CoA synthase 4 (ACSL4) to the nonspecific ASCLs, especially ASCL1 (5).

The observed increase in the number of LDs during the first phase of HSC activation can in principle be accomplished by the de novo synthesis of the new LDs (6) or fission of existing large LDs (7). We previously suggested that HSCs contain two pools of LDs, a preexisting and a dynamic pool of LDs. The preexisting LD pool is characterized by a larger average size of the LD diameter, the presence of REs, and the involvement of its synthesizing enzyme LRAT (8, 9). The dynamic LDs were shown to be smaller than preexisting LDs and have a dynamic lipid metabolism, with new TAG synthesis and hydrolysis at relatively high rates (9). We previously demonstrated that the observed increase in number of LDs during the first phase of HSC activation is likely the result of a decrease of the preexisting pool of LDs and concomitant presence of a highly dynamic pool of lipid droplets. In the dynamic LD pool, DGAT1 and ATGL (also known as PNPLA2) are involved in the synthesis and breakdown of newly synthesized TAGs, respectively (9). The degradation pathway of the dynamic LD pool resembles the well known mechanism of LD breakdown in adipose cells. In these cells key roles were assigned to ATGL, its co-activator...
CGI-58, and hormone-sensitive lipase (10). The first two proteins are known to have a more general function as deficiencies in either one leads to neutral lipid storage diseases (11). Rat HSCs were shown to express ATGL but not hormone-sensitive lipase (9, 12).

In mouse and rat HSCs, ATGL was found to be involved specifically in breakdown of newly synthesized TAGs but not in degrading TAGs in the preexisting LD pool. This suggests the existence of another lipolysis pathway (9). In mouse HSCs, lipid breakdown was shown to be partially mediated by a lipophagic pathway, as inhibition of autophagy increased the amount of LDs (13–15). Because inhibition of autophagy was shown to impair HSC activation in mice and this effect could be partially reversed by the addition of exogenous FAs, it was suggested that LD breakdown is required to fulfill the energy demands of HSCs during activation (14).

The lipase active in lipophagy is thought to be lysosomal acid lipase (LAL), which is encoded by the Lipa gene (16) and which is also responsible for the degradation of lipoprotein derived CEs and TAGs taken up by endocytosis (17). Targeted deletion of Lipo in mice leads to severe CE and TAG accumulation in hepatocytes (18), and LAL deficiency in humans results in either Wolman disease or its milder variant, cholesteryl ester storage disease (CESD), depending on the mutation in the Lipa gene (19).

In this study we addressed the question of whether inhibition of LAL affects lipid metabolism in HSCs and the activation process in rat and mouse HSCs. We, therefore, studied the effect of the LAL-specific inhibitor lalistat (20–22) on HSC lipid metabolism and activation, and we made use of a knock-out strain of mice deficient in LAL.

**Results**

**Neutral lipid breakdown in HSCs by lysosomal acidic lipase**

The contribution of LAL/Lipa to neutral lipid breakdown was studied by incubating rat HSCs with the LAL-specific inhibitor lalistat (100 μM) during the early activating phase (days 1–7). As shown in Fig. 1A, lalistat caused a 3–4-fold increase in the levels of all neutral lipids including TAGs, CEs, and REs. Lalistat (100 μM) proved to be non-toxic to the HSCs, as the 6-day incubation had no effect on cell viability (98 ± 13% of control viable cells). The increase in TAGs and CEs could be (partially) the result of uptake of exogenous lipids, e.g., as lipoproteins, from the medium that are also degraded by LAL. To determine whether the observed increase in neutral lipids during HSC activation by lalistat resulted from inhibition of breakdown of extracellular or intracellular neutral lipids, we limited the contribution of exogenous lipids during the inhibitor treatment by culturing the cells in medium with delipidated serum. Under these conditions the levels of TAG species containing PUFAs and the levels of CEs were much lower (Fig. 1B), in line with the notion that PUFA-TAGs are synthesized from exogenous PUFAs (5) and that CEs are derived from lipoproteins from the medium. The levels of non-PUFA TAGs were less affected by growing the HSCs in delipidated medium. Nevertheless, the levels of these non-PUFA TAGs and REs were increased by lalistat to similar levels when compared with cells grown in normal medium (cf. Fig. 1, A and B). During the incubation with delipidated medium, TAGs might still be (re)synthesized from endogenous FAs, derived from TAG and phospholipid breakdown. We, therefore, also studied the effect of lalistat in delipidated medium and in the presence of T863, a DGAT1 inhibitor that was shown to inhibit TAG synthesis in rat HSCs for >80% (9). When re-synthesis is inhibited, the amount of non-PUFA TAGs is almost halved during the 3-day incubation, similar to the ~60% decrease in RE levels (Fig. 1C). Lalistat completely prevented the degradation of these lipids, clearly indicating that this LAL inhibitor prevented the breakdown of preexisting lipids. To determine the specificity of lalistat, we tested the pyrazole-methanone compounds E4, F2, and H4, which have been described to inhibit LAL (23). As shown in Fig. 1D, the potency of the compounds to increase the level of CEs, a clear hallmark of LAL-inhibition (18), was correlated to their capacity to increase the levels of TAGs and REs. The lalistat-induced accumulation of non-PUFA TAGs and REs is opposite from our previous observation that HSCs from ATGL-deficient mice accumulated PUFA-TAGs but not non-PUFA TAGs and REs (9). As ATGL is involved in the turnover of lipids in the dynamic LD pool (9), our combined results indicate that Lalistat does not affect the dynamic LD pool but, rather, the preexisting LD pool.

The dynamic LD pool can be readily labeled by the addition of deuterated fatty acids to the medium resulting in rapid incorporation of the stable isotope in this pool of lipids (9). To investigate directly whether the LAL inhibitor could inhibit the dynamic TAG pool, we labeled freshly isolated rat HSCs for 2 days with 25 μM D4-palmitate in medium containing 10% fetal bovine serum followed by a 2-day chase without stable isotope-labeled palmitate but in the presence of lalistat or orlistat, a general lipase inhibitor formerly known as tetrahydrodrispstatin (20, 24). As shown in Fig. 2A, a large percentage of TAGs can be labeled with D4-palmitate. In the absence of inhibitors, the doubly labeled TAG species are almost completely degraded during the 2-day chase (Fig. 2, A and B). The general lipase inhibitor orlistat could inhibit the degradation of the newly made TAGs almost completely. However, lalistat did not significantly affect the degradation of the labeled TAGs. Both lalistat and orlistat increased the amount of unlabeled TAGs during the chase to a similar level (Fig. 2). This suggests that lalistat preferentially inhibits the degradation of a pool of unlabeled TAGs, whereas orlistat affects the breakdown of both a pool of labeled (i.e., newly synthesized) and unlabeled (preexisting) TAGs.

**Lalistat affected LD morphology and localization**

The observed lalistat-induced increase of a specific pool of neutral lipids might lead to changes in LD size and/or number. Examination of lipid droplet morphology in HSCs by fluorescence microscopy showed that lalistat induces an increase in the number, but not in the size of the of LDs, whereas orlistat increased both parameters, resulting in a specific increase in big LDs (>2 μm) (Fig. 3). These data are in agreement with the fact that these drugs affect different lipid breakdown pathways. To verify that lalistat inhibits lipid breakdown in the lysosomal compartment, we imaged LDs in HSCs after
staining the acidic compartments with Lysotracker red (Fig. 4). In control cells we observed that ~20% of the Lysotracker positive structures were close to RE-containing LDs, but colocalization was not observed. Only in the HSCs incubated with lalistat did we detect a consistent colocalization of these structures, indicating that the lipids accumulated inside lysosomes (Fig. 4 and supplemental Fig. S1). After incubation with lalistat we also noticed HSCs that clearly contained two populations of LDs, one that contained retinoids (UV autofluorescent), and one that did not (Fig. 4A and supplemental Fig. S1). Typically, the latter population was localized at the periphery of the cell, whereas the former was present around the nucleus together with the Lysotracker red-positive structures.

Figure 1. The lysosomal lipase inhibitor lalistat increased the levels of neutral lipids in rat HSCs. A and B, isolated rat HSCs were incubated from day 1 to day 7 in medium with 10% FBS (A) or 10% delipidated FBS (delip) (B) containing vehicle (DMSO) or 100 μM lalistat (lalist). C, isolated rat HSCs were incubated from day 1 to day 4 in medium with delipidated FBS and 10 μM DGAT1 inhibitor T863 additionally containing vehicle (DMSO; T863; white bars) or 100 μM lalistat (T863 + lalist; gray bars). D, isolated rat HSCs were incubated from day 1 to day 7 in medium with 10% FBS containing vehicle (DMSO) or 10 μM pyrazole-methanone compounds E4, F2, or H4. Subsequently, neutral lipids were determined by HPLC-MS. The values were normalized to the amount of cholesterol in the sample and expressed relative to the level of the respective lipids present in the control cells incubated with FBS at day 7 (A, B, and D) or to the level of the respective lipids present in the cells at day 1 (C). Data are the means ± S.E. of 6 experiments performed in duplicate (A) or the means ± S.D. of 3 (B and D) or 4 (C) experiments performed in duplicate. *, p < 0.05, t test versus control.
Retinyl ester breakdown in HSCs by lysosomal acidic lipase

The observed inhibitory effect of lalistat on RE degradation and accumulation of REs in lysosomes suggests that the Lipa gene product has RE hydrolytic (REH) activity. Previously, an acidic REH has been described that was different from LAL/Lipa as judged from its insensitivity to bivalent metal ions like bivalent metal ions.

Figure 2. Lalistat did not affect the degradation on newly synthesized TAG species in rat HSCs. Primary rat HSCs were incubated on day 1 with 25 μM D4-palmitate for 48 h. At day 3, part of the cells were harvested (pulse), and the remaining HSCs were chased for 48 h with normal medium with vehicle (DMSO; control), 100 μM lalistat (lalist), or 40 μM orlistat (orlist) and harvested at day 5 (chase). A, single or double deuterium-labeled (gray and dark gray bars) and non-labeled (white bars) TAG fragments with two palmitoyl chains (16:0,16:0,x) were quantitated and expressed as the percentage of all TAG species. B shows breakdown of TAG species from panel A, as the levels of the indicated TAG fragments at day 5, after the chase, were expressed relative to the level of the same TAG species at the beginning of the chase at day 3. Data are the means ± S.D. of five experiments performed in duplicate. *, p < 0.05 paired t test versus control.

Figure 3. Effect of lalistat and orlistat on LD morphology and on the activation marker α-SMA in rat HSCs. A, confocal images of HSCs isolated from rats incubated from day 1 to day 7 with vehicle (day 7), 100 μM lalistat, or 40 μM orlistat. Lipid droplets were stained with LD540 dye (green) and anti-α-SMA antibody (red), and nuclei were stained with Hoechst (blue). In the first panel the red channel was omitted for better visibility of the LDs. Shown are representative pictures from four experiments. B–D, images were analyzed with CellProfiler v2.1.1. B, LD size was expressed in diameter (nm). C, LD numbers were expressed as a ratio of scored lipid droplets and scored nuclei per image. D, LDs distribution is expressed as percentage of LDs with the specified size (in μm). Image analysis was based on at least 50 cells and 3000 lipid droplets per condition. Data are the means ± S.D. *, p < 0.05 t test versus control.
Ca\(^{2+}\) and Mg\(^{2+}\) (25, 26). We also found that the main REH in a homogenate of rat HSCs and rat hepatocytes has an optimum at pH 4 (Fig. 5, A and B). However, we could not observe a difference in inhibition by bivalent cations between the REH in comparison to the CE hydrolase activity, assayed simultaneously (Fig. 5B). We also found that both activities were inhibited by lalistat (Fig. 5B), with a similar IC\(_{50}\). Furthermore, the acidic REH activity was absent in liver homogenates from Lipa\(^{-/-}\) mice and could be induced in CHO homogenates by transfecting the CHO cells with recombinant rat Lipa (Fig. 5, C and D). These latter experiments clearly show that Lipa has REH activity in vitro.

To investigate the effect of Lipa on RE metabolism in HSCs, we attempted to isolate HSCs from Lipa\(^{-/-}\) mice. However, isolation of Lipa\(^{-/-}\) HSCs was not possible, most likely due to the massive accumulation of lipids in the Lipa\(^{-/-}\) livers (18). Therefore, we analyzed the RE content in livers of Lipa-deficient and corresponding WT mice. Surprisingly, we found that despite the 100-fold higher levels of CEs (Fig. 6A), the levels of the REs were similar (retinyl stearate) or lower (retinyl palmitate and retinyl oleate) in the livers of 7-week-old Lipa\(^{-/-}\) mice (Fig. 6B). In older mice (4–5 months; average 20 weeks), the difference between the WT and the Lipa-deficient mice became even larger, as the WT mice continued to accumulate REs, and the Lipa\(^{-/-}\) mice lost most of their REs (Fig. 6B). The low levels of REs in the livers of the 4–5-month-old Lipa\(^{-/-}\) mice were accompanied by a decrease in the expression of LRAT mRNA, considered a marker for quiescent HSCs (27), but not by an up-regulation of the HSC activation marker \(\alpha\)-smooth muscle actin (\(\alpha\)-SMA; Fig. 6, C and D). This suggests that the livers of the Lipa\(^{-/-}\) mice gradually lose their HSCs.

To exclude that the apparent discrepancy between the lack of effect of Lipa knock out in mice in vivo on RE storage and the observed effect of the Lipa-inhibitor lalistat on RE levels in rat HSCs in vitro is caused by species differences between rat and mouse, we compared the effect of lalistat on neutral lipid levels in primary mouse HSCs with its effect on rat HSCs (cf. Figs. 7 and 1A). The levels of REs in primary isolated mouse HSCs at day 1 (5.5 ± 3 nmol of RE/mg of protein) were found to be similar to that in rat HSCs (6 ± 4 nmol of RE/mg of protein). We found that lalistat also caused an increase in TAGs, CEs, and REs in mouse HSCs. In comparison to rat HSCs, the lali-
istat-induced increase in RE level in mouse was somewhat lower (2.5-fold versus almost 4-fold in rat HSCs).

**Rat HSCs have an active autophagy pathway that is required for cell survival**

Determination of Lipa mRNA expression in quiescent (day 1) and activated (day 7) rat HSCs shows that Lipa mRNA is upregulated during activation *in vitro* (Fig. 8A). Endogenous neutral lipids are thought to traffic to the lysosomal compartment by the autophagy pathway. An active autophagy pathway has indeed been described in activated mouse HSCs (13-15). To investigate the involvement of the autophagy pathway in rat HSCs, we made use of the autophagy marker protein LC3B, which can be detected as two isoforms; one represents the cytosolic LC3B-I and the other one represents LC3B-II, which is conjugated with phosphatidyethanolamine and is present on autophagosomes. The amount of LC3B-II is closely related to the autophagosome number and is a good indicator for activation of the autophagy pathway (28). Primary rat HSCs have a high ratio of the lipidated to unlipidated form of the autophagy protein LC3B already at day 1 and which continues until day 7 (Fig. 8B). As a control, the presence of LC3B-I and LC3B-II in LX-2 cells is shown. LX-2 cells are the human HSC cell line with a mixed phenotype with characteristics that resemble both the quiescent and activated phenotype (29). LX-2 cells have a low lipidated to unlipidated ratio that changes upon stimulation of the autophagy pathway (Fig. 8B). Autophagy was also detected in rat HSCs by Cyto-ID/H23041 staining (supplemental Fig. S2). Cyto-ID-positive structures and lipid droplets are abundantly present in HSCs at day 3, but only in the presence of lalistat colocalization of these structures is observed.

To study the contribution of the autophagy pathway in LD breakdown, we attempted to inhibit this pathway with specific inhibitors including 3-methyladenine (5 mM) and bafilomycin A1 (7.5 nM) and with the inhibitor of lysosomal degradation chloroquine (5 μM). All these inhibitors caused massive death of the rat HSCs within 12 h, although the doses used did not affect the viability of the human stellate cell line LX-2 (results...
When we studied the autophagy inhibitors in rat HSCs at lower concentrations that were tolerated, we could not find an effect of these inhibitors on autophagy or lysosomal acidification as analyzed with the LC3B-I to -II ratio and imaging with Lysotracker red (results not shown). From these data we conclude that rat HSCs in culture have a very active autophagy pathway, already as early as day 1 after isolation. The ratio of lipidated to unlipidated LC3B is markedly lower in mouse HSCs (13, 14), and this may explain the high sensitivity of rat HSCs toward autophagy inhibitors, as autophagy seems more essential for rat HSCs as compared with mouse HSCs, at least under our culture conditions.

We considered the possibility that the essential role of autophagy in rat HSCs is the result of an essential reutilization of nutrients from the autophagy pathway. A highly active autophagy pathway in rat HSCs may, therefore, suggest an active turnover of the preexisting LD pool. To study this in more detail, we took advantage of the RE metabolism in HSCs. We previously showed that retinol is generated from hydrolysis of endogenous REs and is available for re-synthesis of REs in either the preexisting (LRAT-mediated) or dynamic pool (DGAT1-mediated) of LDs (8). Indeed, after the addition of deuterated fatty acids to the cell culture medium, we not only observed an incorporation of D4-labeled palmitate into TAGs (Fig. 2) but also a significant D4-labeling of retinyl palmitate (RP) (~30%) (Fig. 8C). This indicates that a significant part of the retinyl palmitate is re-synthesized from endogenous retinol, derived from the breakdown of endogenous REs, as the medium...
Lysosomal acid lipase in lipid droplet metabolism

Mouse HSCs

![Mouse HSCs](image)

**Figure 7. Effect of lalistat on neutral lipid levels in mouse HSCs.** Isolated mouse HSCs were incubated from day 1 to day 7 in medium with 10% FBS containing vehicle (DMSO; control) and 100 μM lalistat (Lalistat). Subsequently, neutral lipids were determined by HPLC-MS. The values were normalized to the amount of cholesterol in the sample and expressed relative to the level of the respective lipids present in the control cells at day 7. Data are the means ± S.E. of six experiments performed in duplicate. *, p < 0.05 t test versus control.

Lalistat inhibited HSC activation

To investigate whether the change in neutral lipid metabolism by the LAL inhibitors or orlistat has an effect on the activation process, we determined the expression levels of α-SMA. α-SMA is considered a marker for HSC activation and was clearly up-regulated in mouse and rat HSCs at day 7 (9). We observed a clear inhibition of the expression of α-SMA by both lalistat and orlistat in rat HSCs, both on protein and mRNA levels (Figs. 3A and 9). The potency of the LAL inhibitors of the class of pyrazole-methanone compounds, E4, F2, and H4, to inhibit α-SMA expression correlated with their potency to inhibit neutral lipid degradation (cf. Fig. 1D and Fig. 9). In mouse HSCs lalistat, but not orlistat, inhibited HSC activation (Fig. 9). Orlistat was also less effective in mouse HSCs compared with lalistat and compared with its effect in rat HSCs in increasing the levels of TAGs, CE, and REs (results not shown).

It has been reported that TAG degradation is required for the generation of FAs for energy during HSC activation in mouse stellate cell line JS1 (14). We, therefore, tested whether FAs derived from TAGs are required for the energy demand of rat HSCs under our culture conditions by treating the cells with etomoxir, an inhibitor of FA oxidation. However, we did not observe an effect of this inhibitor on rat HSC activation (Fig. 9), although the effectiveness of the drug was confirmed by the observation of a 2-fold increase in TAG levels in the presence of this FA oxidation-inhibitor (results not shown). Thus, we consider it more likely that hydrolysis of a specific lalistat-sensitive LD pool is involved in HSC activation for other reasons.

Discussion

We show here that lalistat, a specific inhibitor of the Lipa gene product LAL, affects the levels of three subtypes of neutral lipids, i.e., CE, TAG, and RE, in rat and mouse HSCs. The lalistat-induced increase in CE is in line with the established function of LAL in degrading CE from lipoproteins in the lysosome (18, 19). As expected, the increase was much lower in medium depleted of lipoproteins. The residual increase in the absence of exogenous lipoproteins may be caused by inhibiting the degradation of CE delivered to the lysosome by the autophagy pathway, similarly to that described in macrophages (16, 30). Orlistat was less potent in comparison to lalistat in inhibiting the breakdown of CE, indicating that it inhibited LAL to a lesser degree in HSCs at the concentration used.

LD pools

The comparison between the effects of the inhibitors lalistat and orlistat on TAG levels clearly indicated the existence of different pools of TAGs. Orlistat was more potent at inhibiting the degradation of newly synthesized TAGs, as judged from its large inhibitory effect on the breakdown of labeled TAGs. In contrast, lalistat was more potent at inhibiting the preexisting lipid pool as it did not inhibit the degradation of newly labeled TAGs but prevented the breakdown of existing TAGs when new TAG synthesis was blocked. We previously showed additional evidence for metabolically different TAG pools in HSCs from studies with ATGL−/− mice and the DGAT1 inhibitor T863 (9). We reported that the TAG lipase ATGL specifically targets newly synthesized PUFA-enriched TAGs, made preferentially by DGAT1 in combination with ACSL4. These newly formed TAGs are likely to form new LDs. By use of lalistat, we now have unmasked two pools of LD by live cell-imaging of rat HSCs: one pool of LD-containing retinoids located predominately round the nucleus and a pool present in the periphery of the HSCs that did not contain REs. The combined breakdown of LDs in one place and re-synthesis in another would explain our previous observations in activated rat HSCs, i.e., that LDs reduce in size but increase in number and are localized in cellular extensions (4). Considering that in activated rat HSCs all LDs have a similar lipid spectrum containing a low amount of REs (4), we have to assume that REs are incorporated in the new LDs. Indeed, from D4-palmitate labeling studies and RE species
distribution we have now evidence that REs, like TAGs, are partly re-synthesized during activation (8).

The lipase inhibitors orlistat and lalistat also caused a different effect on the morphology of the LDs. Lalistat increased the number but not the size of the LDs, whereas orlistat and Atglistatin (9) also increased the size of the LDs. This suggests that inhibition of lipase activity on the new LDs allow them to grow beyond a certain limit maintained under normal conditions by the concerted action of the TAG synthesizing enzyme (presumably DGAT1) and the TAG degrading activity (presumably ATGL). In contrast, lalistat-mediated accumulation of LDs reveals that the autophagy pathway engulfs lipid fragments around 0.8 μm, roughly similar to the size of the newly formed LDs (Fig. 3). This would be compatible with the reported sizes of autophagosomes ranging between 0.50 and 1.5 μm (31, 32) and with the observation in rat HSCs analyzed by EM that the subpopulation of LDs that was surrounded by lysosomes was smaller than the cytosolic LDs (33). A model of lipid metabolism and the formation of the different LD pools in HSCs is depicted in supplemental Fig. S3.

**Lipase and retinol ester hydrolysis**

Besides inhibiting the degradation of CEs and TAGs, lalistat proved to be a potent inhibitor of RE degradation. As we observed REs in the acidic compartment after treatment with lalistat, a lysosomal lipase is involved in the breakdown of REs in activated HSCs. The most likely REH is Lipa/LAL as we found that it has clear REH activity in vitro. These findings are in line with similar results described recently by Grumet et al. (34). The REs are most likely delivered to the lysosomes by the autophagy pathway known to be active in activated HSCs (13–15) (Fig. 8). Unfortunately, we could not assess the contribution of the autophagy pathway in the degradation of REs by using autophagy inhibitors, as these inhibitors affected the viability of the primary rat and mouse HSCs under our conditions.
Data are the means packaged as REs in chylomicrons by intestinal cells. The chylomicrons, composed of multiple stages. Dietary retinoids are initially devoid of RE stores. Retinoid storage in the liver is thought to be other cell types besides activated HSCs. The lower levels of may, therefore, point at a role of LAL in RE degradation in lower storage of REs in the liver of the LAL-deficient mice where it is esterified by LRAT and stored in LDs (35). The consequently, retinol is transferred from the hepatocytes to HSCs, in a supposedly non-lysosomal compartment (37). Subsequently, retinol is transferred from the hepatocytes to HSCs, as in the older mice RE stores were probably decreased due to a loss of quiescent HSCs. The HSCs were not yet fully activated in the 20-week-old Lipa−/− mice, as we found no up-regulation of the HSC activation marker α-SMA. In earlier studies on the Lipa−/− mice, it was described that in young mice (1.5 months) lipid (CE/TAG) was predominantly accumulated in hepatocytes but that in older mice (5–8 months) macrophages became the major lipid-storing cells (38). This suggests that the influx of macrophages might be the cause of the disappearance of quiescent HSCs in the 20-week-old Lipa−/− mice. The absence of quiescent HSCs is probably followed by a fibrotic stage, as in older (24 weeks) Lipadeficient mice clear liver fibrosis was detected (39). Likewise humans with mutations in Lipa are known to develop liver fibrosis (19).

**Lysosomal acid lipase in lipid droplet metabolism**

REs in the livers of the LAL-deficient mice were also recently observed by Grumet et al. (34). They found a different retinoid handling in the intestine as a contributing factor to the lower RE levels in the liver. Furthermore, the here-observed role of LAL in degrading REs in activated HSCs, which have an active autophagy pathway, may be less prominent in quiescent HSCs in a healthy liver.

LRAT expression, a marker for quiescent HSCs (27), was not affected in the young Lipa−/− mice but was lost in the older mice, concomitant with a further loss in REs. This suggests that the REs in the young mice are presumably stored predominantly in HSCs, as in the older mice RE stores were probably decreased due to a loss of quiescent HSCs. The HSCs were not yet fully activated in the 20-week-old Lipa−/− mice, as we found no up-regulation of the HSC activation marker α-SMA. In earlier studies on the Lipa−/− mice, it was described that in young mice (1.5 months) lipid (CE/TAG) was predominantly accumulated in hepatocytes but that in older mice (5–8 months) macrophages became the major lipid-storing cells (38). This suggests that the influx of macrophages might be the cause of the disappearance of quiescent HSCs in the 20-week-old Lipa−/− mice. The absence of quiescent HSCs is probably followed by a fibrotic stage, as in older (24 weeks) Lipa-deficient mice clear liver fibrosis was detected (39). Likewise humans with mutations in Lipa are known to develop liver fibrosis (19).

**Lipa and HSC function**

The effect of lalistat, the pyrazole-methanone compounds E4, F2, and H4 and orlistat on lipid levels in rat and mouse HSCs generally correlated with their effect on HSC activation. Lalistat increased all classes of neutral lipids in both rat and mouse HSCs and attenuated activation in rat and mouse HSCs to a similar, albeit relatively low degree (30–40%, Fig. 9). Orlistat was more potent in rat HSCs as compared with mouse cells both in increasing neutral lipid levels and preventing activation. The inhibitory effect of lalistat and orlistat on rat HSC activation was as effective as another lipase inhibitor, Atglistatin (9). In comparison with lalistat, Atglistatin is more potent in inhibiting TAG breakdown but less potent in preventing RE and CE degradation. Although we cannot exclude the possibility that these drugs affect HSCs activation by other, non-lipid related pathways, their effects on HSC activation correlated with their effect on neutral lipid breakdown. Therefore, it seems that HSCs require an available TAG/RE pool for optimal functioning. This pool may act as a buffer for FAs required for energy (14) or synthesis of membranes or bioactive lipids, like prostanoids. In rat HSCs we could not find evidence for a requirement for FA as a source of energy, as the β-oxidation inhibitor etomoxir did not affect activation. Another possibility would be that the neutral lipids by their physical presence in the cytosol, interfere with the differentiation processes needed for activation, like ER and Golgi expansion. This would also explain that mouse HSCs containing almost no LDs by a lack of LRAT show a normal activation response to liver injury (27).
**Lysosomal acid lipase in lipid droplet metabolism**

**Experimental procedures**

**Reagents**

Lalistat (lalistat-2; 3,4-disubstituted thiadazole carbamate, compound 12) from Rosenbaum et al. (21), was a gift from Paul Helquist (University of Notre Dame). The pyrazole-methanone compounds E4, F2, and H4 were described in VanderVen et al. (23). D4-palmitate and 3-methyladenine were purchased from Cayman Chemical (Ann Arbor, MI). D7-cholesteryl palmitate was from Avanti polar lipids. Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), and penicillin/streptomycin were obtained from Gibco. Bovine serum albumin (BSA) fraction V was obtained from PAA (Pasching, Austria). T863, chloroquine diphosphate salt, bafilomycin A, and paraformaldehyde (PF) were obtained from Electron Microscopy Sciences (Hatfield, PA). LipidTOX Red neutral lipid stain were obtained from Molecular Probes (Eugene, OR), and paraformaldehyde (PF) (8%) was obtained from Electron Microscopy Sciences (Hatfield, PA). FluorSave was purchased from Calbiochem, and all HPLC-MS solvents were from Biosolve (Valkenswaard, The Netherlands). T863, chloroquine diphosphate salt, bafilomycin A, and paraformaldehyde (PF) were obtained from Electron Microscopy Sciences (Hatfield, PA). LipidTOX Red neutral lipid stain were obtained from Molecular Probes (Eugene, OR), and paraformaldehyde (PF) (8%) was obtained from Electron Microscopy Sciences (Hatfield, PA). FluorSave was purchased from Calbiochem, and all HPLC-MS solvents were from Biosolve (Valkenswaard, The Netherlands) with exception of chloroform (Carl Roth, Karlsruhe, Germany) and were of HPLC grade. Silica-G (0.063–0.200 mm) was purchased from Merck. Delipidified FBS was made from FBS by extraction with diisopropyl ether and n-butyl alcohol (FBS/diisopropyl ether/n-butyl alcohol, 10/8/4 v/v/v) followed by extensive dialysis against phosphate-buffered saline (PBS) at 4 °C.

**Animals**

We used adult male Wistar rats (300–400 g) and 10–12-week-old male and female C57BL/6J mice for HSC isolation. Lipa−/− mice were generated as described (18). Procedures of rat and mouse care and handling were in accordance with governmental and international guidelines on animal experimentation and were approved by the Animal Experimentation Committee (Dierexperimentencommissie; DEC) of Utrecht University (DEC numbers 2010.III.09.110, 2012.III.10.100, and 2013.III.09.065).

**HSC isolation and in vitro primary cell culture**

Stellate cells were isolated from livers of rats and mice by collagenase digestion followed by differential centifugation (40). After isolation, HSCs were plated in 24-, 12-, or 6-well plates at a density of 2 × 10^4, 5 × 10^4, or 1 × 10^5 cells/well, respectively. Cells were cultured in DMEM supplemented with 10% FBS, 100 units/ml penicillin, 100 μg/ml streptomycin, and 4 μl/ml Fungizone in a humidified 5% CO₂ incubator at 37 °C and were protected from light by covering with aluminum foil. Medium was changed every 3 days. Cell viability and cytotoxicity was assayed with the Cell Counting Kit-8 according to the instructions provided by the manufacturer (Dojindo Molecular Technologies, Inc., Rockville, MD).

**RNA isolation, cDNA synthesis, and quantitative PCR**

Total RNA was isolated using the RNasy Mini Kit (Qiagen, Venlo, The Netherlands) including the optional on-column DNase digestion (Qiagen RNase-free DNase kit). RNA was dissolved in 30 μl of RNase free water and quantified by a Nanodrop ND-1000 (Isogen Life Science, IJsselestein, The Netherlands). An iScript cDNA Synthesis Kit (Bio-Rad) was used to synthesize cDNA. Primer design and quantitative PCR (qPCR) conditions were as described previously (41). Briefly, qPCR reactions were performed in duplicate using a Bio-Rad detection system. Amplifications were carried out in a volume of 25 μl containing 12.5 μl of 2×SYBR Green supermix (Bio-Rad), 1 μl of forward and reverse primer, and 1 μl of cDNA. Cycling conditions were as follows: initial denaturation at 95 °C for 3 min followed by 45 cycles of denaturation (95 °C for 10 s), annealing (temperature as described in supplemental Table S1 or Tuohetahuntila et al. (9) for 30 s), and elongation (72 °C for 30 s). A melting curve analysis was performed for every reaction. To determine relative expression of a gene, a 4-fold dilution series from a pool of all samples were used. IQ5 Real-Time PCR detection system software (Bio-Rad) was used for data analysis. Expression levels were normalized by using the average relative amount of reference genes. Reference genes used for normalization were based on their stable expression in stellite cells, namely, tyrosine 3-monoxygenase/tryptophan 5-monoxygenase activation protein, zeta (Ywhaz), hypoxanthine phosphoribosyltransferase (Hprt), and hydroxymethylbilane synthase (Hmbs). Primers of reference genes are as described Tuohetahuntila et al. (9), and primers of target genes are listed in supplemental Table S1.

**Immunofluorescence**

Freshly isolated HSCs grown on glass coverslips in 24-well plates at 37 °C for 7 days were fixed in 4% (v/v) PF at room temperature for 30 min and stored in 1% (v/v) PF at 4 °C for a maximum of 1 week. Before staining, HSCs were washed twice in PBS, permeabilized by saponin (0.1% (w/v); Riedel-de Haën, Seelze, Germany), and blocked with 2% BSA in PBS for 1 h at room temperature. After blocking, cells were incubated for 1 h with the primary antibody against α-SMA (50–75 μg/ml), washed again, and incubated for 1 h with a fluorescently labeled secondary antibody (15 μg/ml) supplemented with Hoechst (4 μg/ml) for nuclear counterstaining and lipid droplet dye LD540 (0.05 μg/ml). Thereafter, coverslips were mounted with FluorSave on microscopic slides, and image acquisition was performed at the Center of Cellular Imaging, Faculty of Veterinary Medicine, Utrecht University on a Leica TCS SPE-II confocal microscope. To quantify lipid droplet size and numbers per cell, confocal images of LD540 (lipid droplets) and Hoechst33342 (nuclei) were analyzed with CellProfiler v2.1.1. Recognized lipid droplets and nuclei were overlaid on the original image to confirm the identity. The error rate was <5% for lipid droplets and <2% for nuclei.
Live cell imaging

For live cell imaging, cells (20-µl cell suspensions, ~2 × 10^5 cells/ml) were plated on an 8-well glass-bottom slide from ibidi (Planegg/Martinsried, Germany). Cells were cultured under similar conditions as described above in the presence or absence of lalistat for 3 days. At the 4th day after isolation, media were changed with fresh media 2 h before imaging. Just before imaging lysosomes in combination with LDs, 100 µl of Lysotracker Red DND99 (Life Technologies, final concentration of 75 nM) and Bodipy 493/503 (Molecular Probes, final concentration of 200 nM) were added for 30 min in the incubator. For detection of autophagy the Cyto-ID® Autophagy Detection Kit was used following the protocol supplied by the manufacturer (Enzo Life Sciences, Inc. Farmingdale, NY) with co-staining of the LDs with HCS LipidTOX™ Red neutral lipid dye. Images of the samples were recorded using a NIKON A1R confocal microscope equipped with a humidified imaging chamber set to 5% CO₂ and 37 °C (TOKAI hit, Japan) at the Center for Cell Imaging (CCI), Faculty of Veterinary Medicine, Utrecht University.

REH and cholesteryl esterase activity assay

REH was assayed as described (25). In short, an aliquot of homogenized mouse liver (400 µg of protein), homogenized rat hepatocytes (400 µg of protein), or rat HSCs (16 µg of protein) were incubated in 100 µl of sodium citrate buffer (60 mM; pH 4.1) or HEPES buffer (60 mM; pH 7) at 37 °C in a shaking water bath for 45 min in the presence of 1.9 mM RP and/or 1.5 mM D7-cholesteryl palmitate (D7-CE) incorporated into liposomes. Liposomes were made by dissolving 20 mg of 1,α-l- phosphatidylcholine and 0.5 mg of RP and/or 0.5 mg of D7-CE in chloroform. After sonication and centrifugation, the lipids were suspended in 1 ml of 50 mM NaCl and 10 mM Tris, pH 7.4, by sonicating and centrifuging at 17,300 × g for 10 min to sediment large vesicles. The reaction was stopped by the addition of 100 µl of ethanol, and lipids were determined by HPLC-MS using multiple reaction monitoring (MRM) (8).

Analysis of neutral lipids by HPLC-MS

Lipids were extracted from a total cell homogenate of HSCs grown in a 12-well plate by the method of Bligh and Dyer (42) after the addition of 200 pmol of trentadecanoylglycerol as the internal standard. Extracted lipids were separated in a neutral and phospholipid fraction and analyzed on HPLC-MS as described (9). In short, the neutral lipid fraction was reconstituted in methanol/chloroform (1/1, v/v) and separated on a Kinex/HALO C8-e column by a gradient of methanol/H₂O (5/5, v/v) to methanol/isopropanol alcohol (8/2, v/v). Mass spectrometry of neutral lipids (TAGs, CEs, REs, and cholesterol) was performed using Atmospheric Pressure Chemical Ionization (APCI) interface (AB Sciex Instruments, Toronto, ON, Canada) on a Biosystems API-2000 Q-trap mass spectrometer. The system was controlled by Analyst version 1.4.2 software (MDS Sciex, Concord, ON, Canada) and operated in positive-ion mode. TAG fragments with two non-, single-, and double-labeled palmitoyl chains (16:0,16:0,α) were quantitated by counting ions with m/z of 551, 555, and 559, respectively. Typical TAG species quantitated were: non PUFA, 52:3 (m/z 859) and 54:3 (m/z 885); 1×PUFA, 56:5 (m/z 909) and 58:6 (m/z 935); 2×PUFA 60:9 (m/z 957) and 62:11 (m/z 981). For the quantification of the various (deuterated) RE and CE species, we used MRM in positive-ion mode by monitoring molecule specific transitions as described (8). Specific transitions analyzed are summarized in supplemental Table S2. The quantitated lipids were normalized to the amount of cholesterol or protein in the same sample. Cholesterol was found to be a good marker for both recovery and cellular material, as the cholesterol/protein ratio was found to be constant during HSC culture.

Statistical analysis

Each experiment was performed in duplicate and repeated at least three times. Comparisons of a variable between two groups were made with unpaired or paired Student’s t test depending on whether the data were normalized to a control before analysis. Differences were considered statistically significant for p values <0.05.

Acknowledgments—We acknowledge Jeroen Jansen for technical assistance with the lipid analysis. We also thank Paul Helquist (University of Notre Dame) for donating the lalistat2 compound. Real time quantitative PCR was performed and mouse reference gene primers were provided by the Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University. Images were acquired at the Center of Cellular Imaging, Faculty of Veterinary Medicine, Utrecht University on a Leica TCS SPE-II confocal microscope, and we thank Esther van’t Veld for assistance.

References

1. Blaner, W. S., O’Byrne, S. M., Wongsviroj, N., Kluwe, J., D’Ambrosio, D. M., Jiang, H., Schwabe, R. F., Hillman, E. M., Piantedosi, R., and Libien, J. (2009) Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage. Biochim. Biophys. Acta 1791, 467–473
2. Friedman, S. L. (2008) Hepatic stellate cells: protein, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88, 125–172
3. Pellicoro, A., Ramachandran, P., Iredale, J. P., and Fallowfield, J. A. (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 14, 181–194
4. Testerink, N., Ajat, M., Houweling, M., Brouwers, J. F., Pully, V. V., van Manen, H. J., Otto, C., Helms, J. B., and Vaandragert, A. B. (2012) Replacement of retinyl esters by polyunsaturated triacylglycerol species in lipid droplets of hepatic stellate cells during activation. PLoS ONE 7, e34945

Lyposomal acid lipase in lipid droplet metabolism

Author contributions—M. T. designed, performed, and analyzed the experiments and contributed in the writing of the paper. M. R. M. contributed to the performance and analysis of the lipidomic experiments and the retinoid determinations. B. S. helped with designing and performing of the qPCR experiments. J. F. B. helped with design, performance, and analysis of the lipidomic experiments. R. W. contributed to the design, performance, and analysis of the imaging experiments. M. H. contributed to the design and performance of the HSC isolation and culture and interpretation of the lipidomic data. C. Y. and H. D. contributed to the design and performance of the experiments with the pyrazole-methanone class LAL-inhibitors. A. B. V. and J. B. H. conceived and coordinated the study and wrote the paper. All authors analyzed the results and approved the final version of the manuscript.

J. Biol. Chem. (2017) 292(30) 12436–12448 12447
Lysosomal acid lipase in lipid droplet metabolism

5. Tuohetahuntila, M., Spee, B., Kruitwagen, H. S., Wubbolts, R., Brouwers, J. F., van de Lest, C. H., Molenaar, M. R., Houweling, M., Helms, J. B., and Vaandrager, A. B. (2015) Role of long-chain acyl-CoA synthetase 4 in formation of polyunsaturated lipid species in hepatic stellate cells. *Biochim. Biophys. Acta* 1851, 220–230

6. Wilfling, F., Haas, I. T., Walther, T. C., and Fares R. V., Jr. (2014) Lipid droplet biogenesis. *Curr. Opin. Cell Biol.* 29, 39–45

7. Long, A. P., Manneschmidt, A. K., VerBruggie, B., Dorch, M. R., Minkin, S. C., Prater, K. E., Biggerstaff, J. P., Dunlap, J. R., and Dalhaimer, P. (2012) Lipid droplet de novo formation and fission are linked to the cell cycle in fission yeast. *Traffic* 13, 705–714

8. Ajat, M., Molenaar, M., Brouwers, J. F., Vaandrager, A. B., Houweling, M., and Helms, J. B. (2017) Hepatic stellate cells retain the capacity to synthesize retinyl esters and to store neutral lipids in small lipid droplets in the absence of LRAT. *Biochim. Biophys. Acta* 1862, 176–187

9. Tuohetahuntila, M., Molenaar, M. R., Spee, B., Brouwers, J. F., Houweling, M., Vaandrager, A. B., and Helms, J. B. (2016) ATGL and DGAT1 are involved in the turnover of newly synthesized triacylglycerols in hepatic stellate cells. *J. Lipid Res.* 57, 1162–1174

10. Zechner, R., Kienesberger, P. C., Haemmerle, G., Zimmermann, R., and Lass, A. (2009) Adipose triglyceride lipase and the lipolytic catalytism of cellular fat stores. *J. Lipid Res.* 50, 3–21

11. Schweiger, M., Lass, A., Zimmermann, R., Eichmann, T. O., and Zechner, R. (2009) Neutral lipid storage disease: genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI-58/ABHD5. *Am. J. Physiol. Endocrinol. Metab.* 297, E289–E296

12. Mello, T., Nakatsuka, A., Fears, S., Davis, W., Tsuchamoto, H., Bosron, W. F., and Sanghani, S. P. (2008) Expression of carboxylesterase and lipase genes in rat liver cell types. *Biochim. Biophys. Res. Commun.* 374, 460–464

13. Thoen, L. F., Guimaraes, E. L., Doll, L., Mannai, P., Elj, E., and van Grunsven, L. A. (2011) A role for autophagy during hepatic stellate cell activation. *J. Hepatol.* 55, 1353–1360

14. Hernández-Gea, V., Ghiassi-Nejad, Z., Rozenfeld, R., Gordon, R., Fiel, M. I., Yue, Z., Czaja, M. J., and Friedman, S. L. (2012) Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. *Gastroenterology* 142, 938–946

15. Zhang, Z., Zhao, S., Yao, Z., Wang, L., Shao, J., Chen, A., Zhang, F., and Zheng, S. (2017) Autophagy regulates turnover of lipid droplets via ROS-dependent Rab25 activation in hepatic stellate cell. *Redox Biol.* 11, 322–334

16. Ouimet, M., Franklin, V., Mak, E., Liao, X., Tabas, I., and Marcel, Y. L. (2011) Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. *Cell Metab.* 13, 655–667

17. Brown, M. S., and Goldstein, J. L. (1986) A receptor-mediated pathway for ester storage disease. *J. Lipid Res.* 27, 230–232

18. Rosenbaum, A. I., Cosner, C. C., Mariani, C. J., Maxfield, F. R., Wiest, O., and Helquist, P. (2010) Thiadizole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. *J. Med. Chem.* 53, 5281–5289

19. Hamilton, J., Jones, I., Srivastava, R., and Galloway, P. (2012) A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistan 2. *Clin. Chim. Acta* 413, 1207–1210

20. Vankerchen, B. C., Hermetter, A., Huang, A., Maxfield, F. R., Russell, D. G., and Yates, R. M. (2010) Development of a novel, cell-based chemical screen to identify inhibitors of intraphagosomal lipolysis in macrophages. *Cytometry A* 77, 751–760

21. Borgström, B. (1988) Mode of action of tetrahydropyrostatin: a derivative of the naturally occurring lipase inhibitor lipstatin. *Biochim. Biophys. Acta* 962, 308–316

22. Mercier, M., Forget, A., Grolier, P., and Azaïs-Braesco, V. (1994) Hydrolysis of retinyl esters in rat liver: description of a lysosomal activity. *Biochim. Biophys. Acta* 1212, 176–182

23. Azaïs-Braesco, V., Dodeman, I., Delpal, S., Alexandre-Gouabau, M. C., Partier, A., Borel, P., and Grolier, P. (1995) Vitamin A contained in the lipid droplets of rat liver stellate cells is substrate for acid retinyl ester hydrolase. *Biochim. Biophys. Acta* 1259, 271–276

24. Bligh, E. G., and Dyer, W. J. (1959) A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* 37, 911–917